All News
Only small changes in lipid profile and no change in arterial inflammation (measured by FDG-PET) in both TNFi/MTX and triple therapy groups over a 24 week period in the TARGET trial.
What do you think could account for this? Follow-up period too short?
@RheumNow ABST0254 #ACR22 https://t.co/JMJ7WgXyJX
Julian Segan JulianSegan ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
What's better, #cyclophosphamide or #rituximab in CT-ILD? The RECITAL Trial noted both work, but CYP had more GI side effects (not surprising). The study was just published in NEJM. QR code in image to view.
#plenary abst#003 @rheumnow #ACR22 https://t.co/ZDIWtlc9dY
TheDaoIndex KDAO2011 ( View Tweet)
Important to remember to screen for cancer in patients with idiopathic inflammatory myopathy, esp in high risk pts! Can even consider PET/CT, CT, pelvic US, initially. Question is... will insurances approve all of these tests?
Abs#0002 @RheumNow #ACR22 https://t.co/uvr4jGVTFP
Robert B Chao, MD doctorRBC ( View Tweet)
Consensus for #cancer screening in IIM Presented: For more info, go to this session #CurbsideConsults #ACR22 @rheumnow #myositis https://t.co/vJ82rEX2wk
TheDaoIndex KDAO2011 ( View Tweet)
Pooled data from belimumab RCTs w/>3,000 pts evaluating kidney outcomes vs PLBO
Tagging off BLISS-LN, pooled analysis w/marginal but real benefit to adding BEL in pts with SLE
I offer this to all pts w/SLE LN on MMF, but I do not push it
#ACRbest #ACR22 @RheumNow #0352 https://t.co/QYGgB3ue36
Mike Putman EBRheum ( View Tweet)
Consensus for #cancer screening in IIM Presented: When to Go Beyond Standard and Extended Screening #Plenary #ACR22 @rheumnow #myositis #ExpertOpinionNotData https://t.co/cL6zrMnzT3
TheDaoIndex KDAO2011 ( View Tweet)
Cancer screening in myositis:
the path has always been unclear and inconsistent
Workable consensus recommendations @Dr_Alex_Oldroyd
risk stratification but still extensive investigation burden for most
now need to look at effectiveness including cost
ABST0002 #ACR22 @RheumNow https://t.co/322qnGjB9K
David Liew drdavidliew ( View Tweet)
#ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory myopathy. Enhanced screening for those high risk. Studies needed to assess feasibility i.e. cost, positive and negative predictive value of test etc. @RheumNow https://t.co/G1MyQDMhOa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis https://t.co/h1kp7Z9ynO
TheDaoIndex KDAO2011 ( View Tweet)
Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22
@rheumnow #myositis https://t.co/pPLcsFLtG9
TheDaoIndex KDAO2011 ( View Tweet)
Consensus for CA screening in IIM Presented: Risk factors to consider screening
#Plenary #ACR22 @rheumnow #myositis https://t.co/CDNPaRUpPS
TheDaoIndex KDAO2011 ( View Tweet)
Risk stratification for cancer in myositis
@RheumNow #ACR22 #Plenary https://t.co/j7R7P3PS7c
Julian Segan JulianSegan ( View Tweet)
Some suggested screening tests for malignancy in myositis. Recommendations based on assessment of risk factors
@RheumNow #ACR22 #Plenary https://t.co/B0eASeo8hG
Julian Segan JulianSegan ( View Tweet)
Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless!
It's not flashy but it winds up being the backbone/foundation for many subsequent studies
Need more in other diseases, including sarcoidosis and myositis! @DidemSayginMD
#ACR22 @RheumNow https://t.co/64z7DBFCnX
Mike Putman EBRheum ( View Tweet)
GUSTO 1y follow-up (TCZ +IVMPx3 but no ongoing PNL in new GCA):
initial 24w results disappointing (permanent visual loss x1)
BUT follow-up at 2y: control overwhelmingly maintained in responders
We need to keep asking: can we use less PNL in GCA? When?
ABST0470 #ACR22 @RheumNow https://t.co/smyw2nykO5 https://t.co/d2at0pJlSB
David Liew drdavidliew ( View Tweet)
Xeljanz in PsA (@pfizer funded) #ACR22 @RheumNow
⚠️safety data
-Pancytopenia
-Transaminitis
-Dyslipidemia
-Elevated CPK without #myositis
-Avoid in pregnancy and GI strictures
🤰Stop JAKi at least one month prior to conception🤰
Catherine Sims, MD DrCassySims ( View Tweet)
#ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abst#0001 MIRROR RCT at #ACR22 #plenary
Pts with gout on #pegloticase and #gout
sustained higher urate lowering response in pts cotreated with #MTX
benefit beyond 6 months
@rheumnow https://t.co/rTZ3fPaFJS
Bella Mehta bella_mehta ( View Tweet)
Xeljanz use in AS #ACR22 (@pfizer sponsored) @RheumNow
-Included patients with at least bilateral grade 2 SI or grade 3/4 unilateral SI
-5mg BID Xeljanz
-Significantly more patients had ASAS20/40 response, CRP reduction, & QOL, vs. placebo
-Onset of action noticed at 2 weeks https://t.co/DisKpgR0pt
Catherine Sims, MD DrCassySims ( View Tweet)